Aydogan Balaban, H.Ö.*, Arjune, S.*, Grundmann, F. et al. Developing serum proteomics based prediction models of disease progression in ADPKD. Nat Commun 16, 6646 (2025).
Arjune S, Todorova P, Bartram MP, Grundmann F, Müller RU. Liver manifesations in Autosomal Dominant Polycystic Kidney Disease (ADPKD) and their impact on quality of life. CKJ
Arjune S, Lettenmeier K, Todorova P, Späth MR, Mahabir-Brenner E, Grundmann F, Müller RU. Inflammatory cytokines in patients with autosomal dominant polycystic kidney disease (ADPKD). Kidney360
Kretschmer AC, Arjune, S* & Hanßen R. Konservative Adipositastherapie. Die Diabetologie (2024). doi: 10.1007/s11428-024-01160-6
Arjune S*, Späth MR*, Oehm S, Todorova P, Schunk SJ, Lettenmeier K, Chon SH, Bartram MP, Antczak P, Grundmann F,
Fliser D, Müller R. DKK3 as a potential novel biomarker in patients with autosomal polycystic kidney disease *Authors contributed equally, Clinical Kidney Journal, Volume 17, Issue 1, January 2024, sfad262,
Arjune S*, Oehm S*, Todorova P, Gansevoort RT, Bakker SJL, Erger F, Benzing T, Burst V, Grundmann F, Anzczak P, Müller RU. AD(H)PKD - Copeptin as biomarker in patients with autosomal-dominant polycystic kidney disease (ADPKD) *Authors contributed equally, Clinical Kidney Journal, sfad118, doi.org/10.1093/ckj/sfad118
Arjune S*, Todorova P*, Boehm V Schmidt J, Krauß D, Hendrix C, Grundmann F, Müller RU. An in-depth analysis of the interaction between determinants governing urine volume in patients with ADPKD on tolvaptan and its impact on quality of life. *Authors contributed equally, Kidney Int Rep (2023) -, -–-; doi.org/10.1016/j.ekir.2023.05.011
